PMD-026 (RSK1 inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-21 — Therapeutic RSK1 Targeting in Myelofibrosis: Phase Ib dose-escalation trial (3+3 design with dose expansion n=6) of oral PMD-026, a first-in-class RSK1 inhibitor, is underway in myelofibrosis to identify RP2D; no efficacy or safety data reported yet. (novelty: 4)
Open questions
Related
Contributing findings
Therapeutic RSK1 Targeting in Myelofibrosis
21-apr-2026
novelty 4
per-area 5
introduces